Breakthrough in TB Control: 83% Incidence Drop Achieved Through Targeted Screening and Preventive Therapy

In a landmark prospective study published in The Lancet Regional Health – Southeast Asia, Dr. Kunchok Dorjee and his international team have demonstrated the transformative power of comprehensive tuberculosis (TB) screening and preventive treatment in high-risk congregate settings across India. Spanning 2017 to 2024, the Zero TB in Kids (ZTBK) program targeted Tibetan refugee communities in schools, monasteries, and nunneries in Himachal Pradesh and Uttarakhand, achieving an 83% reduction in TB incidence—from 576 cases per 100,000 in 2017 to just 97 per 100,000 in 2024. This real-world evidence underscores how existing tools can dramatically curb TB transmission, offering a blueprint for India's National TB Elimination Programme (NTEP) amid ongoing challenges.

The study, involving 20,068 participants over 67,637 person-years, highlights not only direct benefits for those receiving TB preventive therapy (TPT)—an 82% lower risk of developing active disease—but also herd protection, with an 84% drop in TB prevalence among non-recipients. Latent TB infection (TBI) prevalence fell 32%, from 22% to 15.5%, proving the strategy's efficacy even post-COVID disruptions.

TB Burden in India: Context for High-Risk Refugee Communities

India shoulders nearly a quarter of the global TB burden, with an estimated incidence of 195 per 100,000 in 2023—a 17.7% decline since 2015, faster than the global average but short of elimination targets. The NTEP has expanded TPT, boosting treatment success to 87.6% in 2023, yet gaps persist in screening vulnerable groups like refugees in congregate living—schools and religious institutions where close quarters amplify transmission risks.

Tibetan refugees, numbering around 100,000 in India, face elevated risks due to origins in high-TB areas like Tibet and Nepal. Prior to ZTBK, nearly 1 in 5 schoolchildren had TBI, six times the global average for children. These settings mirror broader challenges in India's diverse populations, where undernutrition, migration, and overcrowding fuel outbreaks.

Dr. Dorjee's work bridges academia and public health, drawing from Johns Hopkins' expertise to support local partners like Delek Hospital and the Central Tibetan Administration's Department of Health.

Dr. Kunchok Dorjee: Leading Academic Force in Global TB Elimination

A physician-epidemiologist of Tibetan descent, Dr. Kunchok Dorjee serves as Assistant Professor of Medicine and International Health at Johns Hopkins University. His research centers on TB elimination strategies, particularly preventive treatment and transmission dynamics in refugees. Leading ZTBK since 2017, Dorjee has spearheaded screenings for over 20,000 individuals, reducing TB incidence by 80-87% in Tibetan children across India and Nepal—a model now informing collaborations like the Gupta-Klinsky India Institute's TB Free Schools Initiative.

For aspiring researchers, Dorjee's trajectory—from practicing in Tibetan settlements to NIH-funded projects—exemplifies the impact of interdisciplinary higher education. Explore opportunities in higher ed research jobs to contribute to such vital work, especially in India's burgeoning public health academia.

Funded by NIH-NIAID, STOP TB Partnership, and philanthropy, the study exemplifies university-led innovation addressing real-world crises.

The ZTBK Program: Step-by-Step Screening and Treatment Protocol

ZTBK employed a mobile, community-based model tailored for congregate settings:

• Symptom screening: Initial triage for cough, fever, weight loss via interviews.
• Diagnostic cascade: Sputum/chest X-ray for active TB suspects; Xpert MTB/RIF or culture confirmation.
• TBI testing: Tuberculin skin test (TST ≥10mm positive) for asymptomatics without active TB.
• TPT delivery: 3-month isoniazid-rifapentine (3HR, 2017-18), switched to 4-month rifampicin (4R) for better adherence; 84% uptake in children/adolescents, 51% in adults.
• Follow-up: Annual rescreening for new entrants; longitudinal tracking via unique IDs.

Across 63 sites (22 schools, 31 monasteries, 9 nunneries), 70% participants were school-aged, with high BCG vaccination (98.7%). This rigorous, ethics-approved approach (Johns Hopkins IRB) ensured safety, monitoring side effects like hepatotoxicity.

Striking Results: Quantified Reductions in TB Incidence and Infection

The program's impact was profound:

One screening round slashed TST conversion by 59% in children, 47% in adolescents. Males faced 23% higher TBI risk; TPT conferred 82% protection (aHR 0.18). Unscreened sites post-COVID showed stark baselines: 640/100,000 incidence, 28% TBI—affirming intervention necessity.

Photo by Aman Shrivastava on Unsplash

Herd Immunity and Broader Community Benefits

Beyond individuals, ZTBK generated population-level protection. Non-TPT recipients saw 84% TB prevalence drop, evidence of interrupted transmission chains. This herd effect persisted through COVID pauses (2020-21), when resurgence hit unscreened sites hardest, dropping sharply post-rescreening.

Such outcomes align with NTEP's TPT push, where household contacts receive priority, but congregate settings like prisons/schools lag. Scaling ZTBK could avert thousands of cases annually, per WHO models for high-burden locales.

Academic researchers can leverage these insights; check academic CV tips for public health roles advancing TB strategies.

Overcoming Challenges: COVID Disruptions and Comorbidity Barriers

Pandemic halts reversed gains temporarily—TBI rose to 18.3% in 2022—but rapid rescreening restored trajectories. Lower TPT uptake in seizure disorders (69% less likely) and hepatitis B (29% less) signals needs for tailored regimens/guidelines.

• High adherence (95% completion) with shorter 4R vs 3HR.
• Minimal adverse events (2.5% hepatotoxicity, managed).
• Equity gaps: Males higher risk, adults lower uptake.

Lessons for India's diverse contexts: Integrate mental health/nutrition support, as undernutrition exacerbates TB.

Implications for India's National TB Elimination Programme

NTEP's progress—detection up to 86.3%, TPT for 10M+ since 2018—benefits from ZTBK evidence. Yet, ~2.8M missed cases persist; congregate screening fills gaps. Propose: Mandate annual TBI surveillance in schools/monasteries, subsidize TPT nationwide.

Johns Hopkins-India ties, via Gupta-Klinsky, exemplify university contributions. For faculty eyeing India, India higher ed jobs in epidemiology abound.

Case Studies: Real-World Transformations in Tibetan Settlements

In Dharamshala schools, pre-ZTBK TB clusters disrupted classes; post-intervention, zero outbreaks since 2022. A monastery saw 15% TBI drop after two rounds, freeing resources for education. These anecdotes, backed by data, illustrate scalability to urban slums/prisons.

Stakeholders praise: CTADOH notes cultural sensitivity key; NTEP partners eye replication.

Future Outlook: Scaling Research and Policy for TB-Free India

WHO End TB goals demand 90% incidence cuts by 2035; ZTBK exceeds via surveillance-TPT loops. Next: AI diagnostics, shorter regimens (3HP trials), genomic tracking. Universities must train interdisciplinary experts—faculty positions in TB research grow.

Optimism tempers realism: Fund comorbidities, monitor resistance. Dorjee advocates global adoption for low-HIV, high-TB nations.

Photo by Corey Young on Unsplash

Actionable Insights for Researchers, Policymakers, and Educators

• Prioritize congregate TBI screening annually.
• Adopt 4R/3HP for high adherence.
• Track herd effects longitudinally.
• Collaborate academia-NGO-government.
• Invest in PhD training: postdoc advice.

Rate professors shaping TB policy via Rate My Professor. Job seekers, browse university jobs in public health.

This study cements Dr. Dorjee's legacy, urging bolder TB strategies. For career guidance, visit higher ed career advice.